Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy
2018-000464-29Phase 3Completed
- Sponsor
- Astria Therapeutics
- Start
- Sep 2018
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Edasalonexent with Placebo (2 arms). Primary endpoint: Change from baseline in North Star Ambulatory Assessment. Started Sep 2018; status: completed.
02
Drugs
edasalonexent
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2018-000464-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000464-29.